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Summary
Background Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in 
allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre-
existing natural immunity. Our aim was to determine whether vaccine-induced immunity could do likewise.
Methods We undertook a phase-2 randomised placebo controlled trial in adults awaiting kidney or liver transplantation 
at the Royal Free Hospital, London, UK. Exclusion criteria were pregnancy, receipt of blood products (except albumin) in 
the previous 3 months, and simultaneous multiorgan transplantation. 70 patients seronegative and 70 seropositive for 
cytomegalovirus were randomly assigned from a scratch-oﬀ  randomisation code in a 1:1 ratio to receive either 
cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant or placebo, each given at baseline, 1 month and 6 months 
later. If a patient was transplanted, no further vaccinations were given and serial blood samples were tested for 
cytomegalovirus DNA by real-time quantitative PCR (rtqPCR). Any patient with one blood sample containing more than 
3000 cytomegalovirus genomes per mL received ganciclovir until two consecutive undetectable cytomegalovirus DNA 
measurements. Safety and immunogenicity were coprimary endpoints and were assessed by intention to treat in patients 
who received at least one dose of vaccine or placebo. This trial is registered with ClinicalTrials.gov, NCT00299260.
Findings 67 patients received vaccine and 73 placebo, all of whom were evaluable. Glycoprotein-B antibody titres 
were signiﬁ cantly increased in both seronegative (geometric mean titre 12 537 (95% CI 6593–23 840) versus 
86 (63–118) in recipients of placebo recipients; p<0·0001) and seropositive (118 395; 64 503–217 272) versus 
24 682 (17 909–34 017); p<0·0001) recipients of vaccine. In those who developed viraemia after transplantation, 
glycoprotein-B antibody titres correlated inversely with duration of viraemia (p=0·0022). In the seronegative patients 
with seropositive donors, the duration of viraemia (p=0·0480) and number of days of ganciclovir treatment 
(p=0·0287) were reduced in vaccine recipients. 
Interpretation Although cytomegalovirus disease occurs in the context of suppressed cell-mediated immunity 
post-transplantation, humoral immunity has a role in reduction of cytomegalovirus viraemia. Vaccines containing 
cytomegalovirus glycoprotein B merit further assessment in transplant recipients.
Funding National Institute of Allergy and Infectious Diseases, Grant R01AI051355 and Wellcome Trust, Grant 078332. 
Sponsor: University College London (UCL). 
Introduction
Cytomegalovirus is an important pathogen for women of 
childbearing age and for allograft recipients, two 
populations in whom development of a vaccine has been 
rated as high priority.1–3 The life-long latency and ability 
to reinfect despite pre-existing natural immunity make 
the production of a vaccine against cytomegalovirus 
challeng ing.4,5 In the allograft recipient, viraemic 
dissemin ation can cause end-organ disease, such as 
hepatitis, pneumonitis, gastroenteritis, and retinitis6,7 
and can predispose to transplant rejection. The antiviral 
drug ganciclovir and its prodrug valganciclovir potently 
inhibit cytomegalovirus replication. Two strategies can 
be deployed to control end-organ disease related to the 
virus: antiviral prophylaxis, in which the drug is given 
routinely from the time of transplantation; or pre-emptive 
treatment, in which patients are monitored to detect the 
virus in blood and treatment is begun once a deﬁ ned 
quantity of viral load is detected. Both strategies are 
eﬀ ective in control of such disease.8–13
Cytomegalovirus infection after transplantation might 
originate from the donor or from reactivation in the 
recipient. Infection might cause either primary infection 
in recipients who are initially seronegative for the virus 
or reinfection with a new strain in seropositive recipients.4 
The most serious clinical eﬀ ects result from primary 
infection, followed by reinfection, with reactivation being 
the least likely to cause end-organ disease.4 Thus, most 
end-organ disease arises from donor-derived virus. This 
hierarchy of risk occurs because natural immunity before 
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trans plantation provides substantial protection against 
virus replication after transplantation14–16 and a high viral 
load is needed to cause end-organ disease.17–19
Given that natural immunity before transplantation 
can modulate the pathogenicity of cytomegalovirus after 
transplantation,16 we tested whether vaccine-induced 
immunity could do likewise. No correlates of protective 
immunity that deﬁ ne whether a given vaccine is 
suﬃ  ciently immunogenic exist to justify a phase-3 
clinical trial of eﬃ  cacy. We therefore designed a phase-2 
proof-of-concept study, selecting a group of patients given 
pre-emptive treatment as standard of care, so that no 
patient received antiviral prophylaxis. This study focused 
on pharmacodynamics rather than pharma cokinetics. 
Methods
Patients studied
In this phase-2 randomised placebo-controlled trial, 
patients were recruited from the kidney or liver transplant 
waiting lists at the Royal Free Hospital, London, UK, 
between Aug 3, 2006, and Oct 30, 2008. Exclusion criteria 
included: pregnancy (a negative pregnancy test was 
required before each vaccine dose); receipt of blood 
products (except albumin) in the previous 3 months, and 
Vaccine group Placebo group
 Cytomegalovirus 
positive
Cytomegalovirus 
negative
Cytomegalovirus 
positive
Cytomegalovirus 
negative
Total number of patients 32 35 38 35
Organ awaiting transplantation
Liver 10 (31%) 15 (43%) 13 (34%) 16 (46%)
Kidney 22 (69%) 20 (57%) 25 (66%) 19 (54%)
Sex
Male 16 (50%) 22 (63%) 17 (45%) 27 (77%)
Female 16 (50%) 13 (37%) 21 (55%) 8 (23%)
Age (years) 55 (12) 49 (12) 52 (12) 48 (13)
Race
Caucasian 24 (75%) 32 (91%) 22 (58%) 33 (94%)
Black 1 (3%) 0 (0%) 7 (18%) 1 (3%)
Asian 5 (16%) 3 (9%) 5 (13%) 0 (0%)
Other 2 (6%) 0 (0%) 4 (11%) 1 (3%)
Number of vaccinations received
1 1 (3%) 1 (3%) 4 (11%) 1 (3%)
2 12 (38%) 18 (51%) 12 (32%) 8 (23%)
3 19 (59%) 16 (46%) 22 (58%) 26 (74%)
Days from vaccine 1 to vaccine 2 (median, range) 32 (21–118) n=31 35 (22–274) n=34 30 (21–119) n=34 31 (23–241) n=34
Days from vaccine 1 to vaccine 3 (median, range) 186 (154–416) n=19 188 (147–224) n=16 188 (167–298) n=22 188 (151–375) n=26
Total number of patients who proceeded to transplantation 
during study period
18 23 22 15 
Organ transplanted
Liver 8 (44%) 11 (48%) 10 (46%) 10 (67%)
Kidney 10 (56%) 12 (52%) 12 (55%) 5 (33%)
Sex
Male 7 (39%) 15 (65%) 7 (32%) 13 (87%)
Female 11 (61%) 8 (35%) 15 (68%) 2 (13%)
Age at transplantation (years) 53 (12) 50 (13) 50 (12) 49 (12)
Race
Caucasian 12 (67%) 22 (96%) 14 (64%) 15 (100%)
Black 1 (6%) 0 (0%) 2 (9%) 0 (0%)
Asian 4 (22%) 1 (4%) 3 (14%) 0 (0%)
Other 1 (6%) 0 (0%) 3 (14%) 0 (0%)
Number of doses of vaccine or placebo received before transplantation
1 0 (0%) 1 (4%) 1 (5%) 0 (0%)
2 9 (50%) 16 (70%) 8 (36%) 6 (40%)
3 9 (50%) 6 (26%) 13 (59%) 9 (60%)
Days from vaccine 1 to transplantation (median, range) 216 (40–636) 123 (22–604) 199 (8–1134) 262 (36–1231)
(Continues on next page)
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simultaneous multiorgan transplantation. The study was 
approved by the Research Ethics Committee and all 
patients gave written informed consent.
Randomisation and masking
After patient consent, a pharmacist allocated placebo or 
vaccine using a scratch-oﬀ  randomisation code provided 
by Sanoﬁ  Pasteur. The randomisation (ratio 1:1) was 
stratiﬁ ed by cytomegalovirus status (seropositive vs sero-
negative) and by transplanted organ (renal vs liver). 
Because the vaccine (white emulsion) and the placebo 
(colourless liquid) appeared diﬀ erent, a blind-observer 
procedure was followed for product preparation and 
administration and safety assessment. Speciﬁ cally, one 
investigator prepared the vaccine by transferring 0·35 mL 
of the MF59 emulsion to the 0·35 mL of cytomegalovirus 
glycoprotein-B antigen vial and then withdrawing 0·5 mL 
to vaccinate the patient. A second investigator (unaware 
of whether vaccine or placebo had been given) was then 
responsible for safety assessment. The material to be 
injected was obscured from patients who were asked to 
face away from the injection site.
Procedures
The ﬁ rst patient was vaccinated on Aug 3, 2006. Vaccine 
doses containing 20 μg of recombinant cytomegalovirus 
glycoprotein B plus 9·75 mg of MF59 adjuvant were 
given intramuscularly at 0, 1, and 6 months, which was a 
dose schedule that had been previously assessed in 
healthy volunteers.20–22 The placebo was normal saline. 
Once a patient was transplanted, which could occur 
before all three doses were given, no further doses were 
given. Patients received a diary card to record solicited 
local (injection site pain, erythema, and swelling) and 
systemic (headache, fever, and myalgia) symptoms for 
7 days after every injection and a thermometer and ruler 
to help with these measure ments. These adverse events 
were classiﬁ ed as mild, moderate, or severe by reference 
to a pre-speciﬁ ed chart. Patients were telephoned 48 h 
after every injection to remind them to complete the 
diary cards. Any serious adverse events that occurred 
within 28 days after an injection were recorded, and so 
were unexpected serious adverse reactions occurring at 
any time until the trial ended in September, 2009. 
The principal investigator was responsible for study 
design, protocol development and, together with the statis-
tician, prepared the prespeciﬁ ed data analysis plan. Adverse 
and serious adverse events were tabulated and presented 
to a Data Safety Committee on six occasions. This Com-
mittee felt it was necessary to break the code in April, 2009, 
to ensure that there was no imbalance in the number of 
deaths occurring in each study group, but all investigators 
remained unaware of the allocation until the formal 
breaking of the code in September, 2009, after all partici-
pants had completed the vaccination phase of the study.
Antibodies against glycoprotein B were measured by 
enzyme immunoassay with a method similar to that 
described in detail elsewhere23 and expressed as geometric 
mean titres. Patients were managed according to routine 
clinical standard of care at this institute. Whole blood 
samples were requested twice a week from inpatients and 
at all subsequent outpatient visits, which were typically 
scheduled every week for 4 weeks then every 2 weeks until 
day 90. If cytomegalovirus viraemia was detected, patients 
Vaccine group Placebo group
 Cytomegalovirus 
positive
Cytomegalovirus 
negative
Cytomegalovirus 
positive
Cytomegalovirus 
negative
(Continued from previous page)
Immunosuppressive drugs administered*
Basiliximab 5 (28%) 9 (39%) 7 (32%) 3 (20%)
Tacrolimus 14 (78%) 23 (100%) 22 (100%) 13 (87%)
Azathioprine 5 (28%) 6 (26%) 7 (32%) 4 (27%)
Mycophenolate mofetil 10 (56%) 17 (74%) 16 (73%) 10 (67%)
Prednisolone 13 (72%) 21 (91%) 19 (86%) 11 (73%)
Methylprednisolone 10 (56%) 16 (70%) 18 (82%) 9 (60%)
Available follow-up by PCR since transplantation (days)
Median (range) 93 (89-228) 97 (15–138) 95 (45–173) 95 (20–278)
Cytomegalovirus status of donor
Positive 7 (39%) 11 (48%) 15 (68%) 5 (33%)
Negative 11 (61%) 12 (52%) 7 (32%) 10 (67%)
Transplantation type
Cadaver 13 (72%) 17 (74%) 16 (73%) 14 (93%)
Live person 5 (28%) 6 (26%) 6 (27%) 1 (7%)
Data are number (%), mean (SD) unless otherwise indicated. *If drugs known, otherwise we assumed that no drugs were administered.
Table 1: Baseline characteristics according to patients’ cytomegalovirus status and randomisation group
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were monitored closely until PCR-negative results were 
obtained, and testing reverted to twice weekly in inpatients 
and at all subsequent outpatient visits. Each sample was 
tested by real-time quantitative PCR (rtqPCR) for 
cytomegalovirus DNA as described elsewhere.24
Viraemia was deﬁ ned as a blood sample that was PCR 
positive (cutoﬀ  200 genomes per mL whole blood). If 
viraemia higher than 3000 genomes per mL was detected, 
the patient was treated with twice daily intravenous 
ganciclovir 5 mg/kg (or twice daily oral valganciclovir 
900 mg), with dose adjustment for renal function, until 
cytomegalovirus DNA was undetectable in two consecu-
tive blood samples. The time from the ﬁ rst PCR-positive 
sample until the last PCR-positive sample deﬁ ned 
duration of viraemia, which therefore included days with 
and without pre-emptive treatment. Previous comparisons 
showed that changes in viral load values were 
indistinguishable when patients were treated with 
ganciclovir or valganciclovir.24 Cytomegalovirus end-
organ disease was diagnosed by histopathological demon-
stration of inclusion bodies in aﬀ ected organs25 and, 
from our natural history data,26 was associated with a 
median viral load of 175 500 genomes per mL in blood 
with 37 000 genomes per mL as the lower limit of the 
95% CI. With the 1 day average doubling-time14,15 of 
cytomegalovirus and the timing of sampling twice weekly, 
we aimed to initiate pre-emptive treatment once the viral 
load increased above 3000 genomes per mL to prevent 
viral load reaching 37 000 genomes per mL.
For the studies of immunogenicity, serum samples were 
requested at the time of ﬁ rst injection and 28, 56, 180, and 
208 days later in those who received all three injections. In 
the subset of patients who received transplants, additional 
samples were requested at time of transplantation 
and 7, 35, 63, and 90 days later. The geometric mean titre 
and 95% CI of antibodies measured against glycoprotein B 
was calculated at each timepoint and plotted according to 
patient cytomegalovirus serostatus and randomisation 
group. Neutralising antibodies were measured with 
Towne RC256 (β-galactosidase marker virus) and human 
ﬁ broblast target cells. 
Safety and immunogenicity were co-primary endpoints. 
For secondary endpoints, we postulated that receipt of 
vaccine would decrease the duration or quantity, or both, of 
viraemia when compared with that of placebo. A correlate 
of protective immunity was the tertiary endpoint.
Statistical analysis
Safety and immunogenicity was assessed by intention to 
treat in patients who received at least one dose of vaccine 
or placebo (intention to treat–exposed analysis). No 
interim analyses were planned and no post-hoc analyses 
are presented. The percentage of patients reporting any 
pain (regardless of severity) within a week of ﬁ rst injection 
was compared in the two groups with a χ² test. Tests were 
two-sided and a p value of less than 0·05 was regarded as 
signiﬁ cant. Patients who did not complete a diary card 
were judged to have had pain (missing-equals-failure 
analysis). This analysis was repeated for the occurrence of 
other solicited adverse events (myalgia, redness, site 
swelling, headaches, or fever) within 1 week of the ﬁ rst 
injection. The missing-equals-failure analysis was 
repeated for the percentage of patients reporting pain 
within a week of the second and third doses, but excluding 
those who proceeded to transplantation since this was a 
random event (modiﬁ ed missing-equals-failure approach). 
Next, the results from all three injections were 
summarised descrip tively according to severity (and thus 
each individual could have up to three measurements 
reported for each adverse event). Those who did not 
complete a diary card were excluded from the combined 
analysis of degree of severity.
For the studies of immunogenicity, because the outcome 
was numerical, a missing-equals-excluded approach was 
taken. The main timepoint of interest was decided a priori 
to be 1 month after the second dose of vaccine (day 56) 
and diﬀ erences between groups were compared by a 
2-sample t test (with log-transformed data to ensure 
normality) stratiﬁ ed by the patients’ cytomegalovirus 
status. The investigation was powered so that about 
30 patients with cytomegalovirus viraemia after trans-
plantation would be expected, on the basis of our previous 
natural history data.16 A total sample size of 140 patients 
was required to expect about 30 patients to develop 
viraemia. Analyses were done with SAS version 9.2 (SAS 
Institute Inc, Cary, NC). This trial is registered with 
ClinicalTrials.gov, NCT00299260.
490 patients assessed
for eligibility
140 randomised
67 assigned to receive
cytomegalovirus vaccine
67 assessed
35 received 3 doses
30 received 2 doses
2 received 1 dose
12 excluded
4 died
4 at patient’s request
2 referred elsewhere
2 ill health
14 awaiting
transplantation
16 excluded
6 died
3 at patient’s request
2 referred elsewhere
4 ill health
1 lost to follow-up
20 awaiting
transplantation
73 assessed
48 received 3 doses
20 received 2 doses
5 received 1 dose
41 proceeded to transplantation 37 proceeded to transplantation
41 evaluable 37 evaluable
73 assigned to receive
placebo
Figure 1: Trial proﬁ le at the time of analysis
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Role of the funding source
The sponsors of the study and the funding source had no 
role in the study design, data collection, data analysis, data 
interpretation, writing of the manuscript, or in the 
decision to submit to publication. PG, CS, VE, RM had 
full access to all the data. All authors reviewed the report 
and had ﬁ nal responsibility for the decision to submit for 
publication. 
Results
No major imbalances in demographic or clinical features 
were noted between seropositive or seronegative patients 
randomly assigned to vaccine or placebo (table 1). Figure 1 
shows the trial proﬁ le at Dec 31, 2009. All 140 randomised 
patients were evaluable for the two co-primary endpoints 
of safety and immunogenicity. Of the 67 patients randomly 
assigned to vaccine, all 67 (100%) had not proceeded to 
transplantation or death before the ﬁ rst schedule dose, 
66 (98·5%) had not done so before the second dose, 
and 40 (59·7%) had not done so before the third dose. For 
the 73 patients randomly assigned to placebo, these 
ﬁ gures were 73 (100·0%) before the ﬁ rst scheduled dose, 
72 (98·6%) before the second dose, and 55 (75·3%) before 
the third dose; these numbers were the denominators in 
the modiﬁ ed missing-equals-failure analysis. 34 patients 
were still awaiting transplantation as of Dec 31, 2009. 
78 patients proceeded to transplantation, all of whom 
were evaluable, with a median (range) of 95 (15 278) days 
of follow-up.
The geometric mean titre of glycoprotein-B antibodies 
(ﬁ gure 2) was signiﬁ cantly increased 1 month after the 
second dose (day 56) in those initially seronegative 
(geometric mean titre of 12 537 in vaccine recipients 
vs 86 in placebo recipients; p<0·0001) or initially sero-
positive (118 395 vs 24 682; p<0·0001). The geometric 
mean titre of neutralising antibodies was not signiﬁ cantly 
increased at day 56 in seronegative patients (p=0·10), but 
was signiﬁ cantly increased in the seropositive patients 
(p=0·0037; webappendix p 1), in whom the neutralising 
antibody titres correlated with glycoprotein-B antibody 
titres (webappendix p 2).
Of the 67, 66, and 40 patients from the vaccine group 
who had not been transplanted by the time of vaccine 
administration, eight (12%), 18 (27%), and 20 (50%) did 
not complete a diary card for the ﬁ rst, second, and third 
doses, respectively. For the 73, 72, and 55 evaluable patients 
in the placebo group, these ﬁ gures were ten (14%), 
17 (24%), and 23 (42%). Injection site pain was signiﬁ cantly 
increased after dose 1 (38 of 67 [57%] patients given vaccine 
versus 19 of 73 [26%] patients given placebo; p=0·0002 
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Figure 2: Geometric mean (95% CI) antibody titres measured by glycoprotein-B enzyme-linked immunoassay
(A) Seronegative recipients. (B) Seropositive recipients. Tx indicates the geometric mean titres found at the time of transplantation.
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Figure 3: Inverse correlation of titre of antibodies against glycoprotein B present at the time of 
transplantation with duration of viraemia after transplantation
Only patients with viraemia at any time were selected for this analysis. D–=cytomegalovirus seronegative donor. 
R–=cytomegalovirus seronegative recipient. D+=cytomegalovirus seropositive donor. R+=cytomegalovirus 
seropositive recipient.
See Online for webappendix
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with a risk diﬀ erence of 31% (95% CI 15·1–46·2). Similar 
results were seen after dose 2 (43 of 66 [65%] versus 
23 of 72 [31%]; p<0·0001) and dose 3 (31 of 40 [78%] versus 
28 of 55 [51%] p=0·0083). This trend remained in a 
missing-equals-excluded analysis. The severity of the pain 
was graded from mild to moderate in most cases, did not 
increase with the number of doses, lasted for a similar 
time in patients given vaccine or placebo, and was not a 
reason for requested withdrawal from the study.
When considering the other solicited events after 
administration of the ﬁ rst dose, no evidence was shown 
of increased muscle pain (30 [45%] of 67 events in vaccine 
group vs 23 [32%] of 73 in placebo group; p=0·15), 
headaches (21 [31%] of 67 vs 27 [37%] of 73; p=0·60), 
swelling (16 [24%] of 67 vs 16 [22%] of 73; p=0·94), raised 
temperature (12 [18%] of 67 vs 12 [16%] of 73 p=0·99) or 
redness (19 [28%] of 67 vs 20 [27%] of 73; p=1·00). The 
ﬁ ndings of 277 available diary cards are summarised in 
the webappendix p 3, with each individual contributing 
up to three observations. No individuals completed diary 
cards after progressing to transplantation or after 
withdrawing from the study. Individuals could only have 
a maximum of one of each adverse event per injection, 
but could have more than one diﬀ erent type of adverse 
event and could experience the same adverse event at 
subsequent injection visits. 47 patients (20 given vaccine, 
27 placebo) experienced serious adverse events 
(webappendix pp 4,5), none of which were assessed by 
the principal investigator as related to vaccination. The 
results also summarise the unsolicited adverse events 
reported across all three timepoints. Overall, 108 patients 
(59 given vaccine, 49 placebo) reported 162 adverse events 
(100 in vaccine group, 62 in placebo group). Of these, 
19 adverse events (15 in vaccine group, 4 in placebo 
group) were assessed to be related to vaccination.
After transplantation, 27 of 78 patients developed 
viraemia whose duration correlated inversely with the 
geometric mean titre of glycoprotein-B antibodies 
(ﬁ gure 3). Of the ﬁ ve vaccinees who necessitated treatment 
(ﬁ gure 3), only one had received all three doses of vaccine. 
The patients were well-matched for duration of follow-up 
and number of samples collected (table 2). Vaccinees in 
the subgroup of donor seropositive and recipient 
seronegative had a lower proportion of days on which 
samples were PCR positive (12% of total patient follow-up 
time post-transplantation versus 57%; p=0·0480) and days 
on which treatment was given (13% vs 69%, p=0·0287, 
table 2). The median peak viral load was 6310 genomes 
per mL in recipients of placebo and 562 genomes per mL 
in recipients of vaccine (p=0·34); one placebo recipient 
was excluded from this calculation because she died from 
a surgical complication before reaching a peak viral load. 
Comparison of proportion of days of treatment in (all) 
vaccine versus (all) placebo p=0·31. The magnitude of this 
eﬀ ect is shown in ﬁ gure 4. The proportion of days of post-
transplantation follow-up spent with viraemia (or receiving 
treatment) was calculated for each individual and these 
values were then compared between vaccine and placebo 
Viraemia >200 
genomes per mL
Number 
treated
Median days of 
follow-up 
(range)
Median number 
of samples 
(range)
Days PCR positive/
total person-days of 
follow-up (%)*
Days treated/total 
person-days of 
follow-up (%)*
Seronegative donor, seronegative recipient (n=22)
Placebo (n=10) 0 0 96 (51–115) 13 (6–25) 0/915 (0%) 0/915 (0%)
Vaccine  (n=12) 0 0 105 (15–138) 15 (3–26) 0/1204 (0%) 0/1204 (0%)
p value ·· ·· ·· ·· 1·00 1·00
Seronegative donor, seropositive recipient (n=18)
Placebo (n=7) 2 0 95 (65–157) 20 (8–25) 2/696 (<1%) 0/696 (0%)
Vaccine (n=11) 4 0 93 (89–176) 20 (4–26) 21/1209 (2%) 0/1209 (0%)
p value ·· ·· ·· ·· 1·00 0·59
Seropositive donor, seropositive recipient (n=22)
Placebo (n=15) 6 3 95 (45–173) 17 (8–26) 119/1489 (8%) 135/1489 (9%)
Vaccine (n=7) 4 0 93 (91–228) 14 (7–21) 6/803 (<1%) 0/803 (0%)
p value ·· ·· ·· ·· 0·51 0·22
Seropositive donor, seronegative recipient (n=16)
Placebo (n=5) 5 4 91 (20–278) 19 (5–62) 339/599 (57%) 415/599 (70%)
Vaccine (n=11) 6 5 94 (90–122) 19 (10–24) 128/1069 (12%) 142/1069 (13%)
p value ·· ·· ·· ·· 0·0480 0·0287
N=78 27 12 ·· ·· ·· ··
*Total number of person-days during which any participant had viraemia higher than 200 genomes per mL or received treatment divided by total number of days of 
follow-up for all participants who underwent a transplantation. The proportion of days of post-transplantation follow-up spent with viraemia (or receiving treatment) was 
calculated for each individual. These values were then compared between vaccine and placebo with a Mann-Whitney U test. Comparison of proportion of days of viraemia in 
(all) vaccine versus (all) placebo p=0·99.  
Table 2: Cytomegalovirus viraemia and treatment in subgroups of transplant patients with deﬁ ned donor and recipient serostatus
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groups with a Mann-Whitney U test. Four patients (all 
placebo) had a second discrete episode of viraemia, which 
responded to pre-emptive therapy. Only one patient 
(placebo recipient) developed cytomegalovirus end-organ 
disease. The frequency of CD4 T-cells responsive to 
cytomegalovirus lysate was not increased in vaccinees at 
the time of transplantation (webappendix p 6).
Discussion
The antibody titre produced against the glycoprotein-B 
protein contained in the vaccine was signiﬁ cantly increased 
1 month after the second injection in patients given the 
vaccine compared with those given placebo, both in 
patients who were immunologically naive to 
cytomegalovirus and in those with naturally acquired 
immunity. The antibody titres were still signiﬁ cantly high 
when the subset of 78 patients proceeded to transplan-
tation, and correlated inversely with the duration of 
viraemia. Seronegative recipients with seropositive donors 
had a reduced duration of viraemia when given the vaccine, 
which translated into a reduced number of days on which 
pre-emptive therapy with ganciclovir or valganciclovir was 
given. Although the number of patients in the highest-risk 
donor seropositive, recipient seronegative group was small 
and the diﬀ erences not signiﬁ cant, the major eﬀ ect of the 
vaccine seemed to be on new infections acquired from the 
donor. Thus, we propose that antibodies induced by a 
cytomegalovirus vaccine might be able to bind the virus in 
the donated organ, thereby preventing trans mission to the 
recipient that is suﬃ  cient to cause detectable viraemia after 
transplantation. 
We plan to design a future randomised controlled trial 
to test this possibility formally. It remains to be 
determined whether such antibodies bind and neutralise 
cytomegalovirus virions released from the donated 
organ or whether the antibodies mediate antibody-
dependent cellular cytotoxicity on virus-infected cells 
contained within the donated allograft. We are currently 
testing sera to diﬀ erentiate between these two 
possibilities. 
This phase 2 proof-of-concept study expands the 
limited amount of published information about 
cytomegalovirus vaccines (panel). We minimised 
sources of bias by randomising patients to receive 
vaccine or placebo. Nevertheless, the number of patients 
in each subset is small, so the encouraging results we 
report should be conﬁ rmed in deﬁ nitive phase 3 studies. 
Since viraemia is a prerequisite for development of 
cytomegalovirus disease,14,26 the prevention of viraemia 
should translate into the prevention of end-organ 
disease. This theory cannot be formally studied in 
patients receiving pre-emptive treatment because of the 
low incidence of end-organ disease, but could be 
assessed in patients managed with antiviral prophylaxis, 
some of whom remain at risk of disease once prophylaxis 
is stopped.13,29 A randomised controlled trial of 
prophylaxis with immunoglobulin30 lends support to 
the notion that antibodies can reduce cytomegalovirus 
end-organ disease. The boosting of antibody responses 
in natural seropositive people is also interesting and 
could be assessed in other populations such as women 
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Figure 4: Proportion of days that patients in the three subgroups at risk of CMV infection spent with viraemia 
or received antiviral treatment
A,B, and C show the duration of viraemia. D,E, and F show the duration of antiretroviral therapy. D+R–, D+R+, and 
D–R+ are three groups at risk of primary infection, reinfection, and reactivation, respectively. The numbers below 
each column indicate the number of patients with viraemia (or treatment) divided by the number in the subgroup. 
Note the diﬀ erent values on the Y-axes of panels A and D compared with panels B, C, E, and F. D–=cytomegalovirus 
seronegative donor. R–=cytomegalovirus seronegative recipient. D+=cytomegalovirus seropositive donor. 
R+=cytomegalovirus seropositive recipient.
Panel: Research in context
Systematic review
We searched PubMed with the search terms “cytomegalovirus”, “vaccine”, and “placebo” 
for randomised controlled trials and clinical trials published in English up to March 17, 
2011. Only two double-blind randomised placebo-controlled phase 2 published trials27,28 
have attempted to control cytomegalovirus. In 1994, a study27 of the live attenuated 
Towne vaccine in seronegative allograft recipients reported signiﬁ cantly reduced severity 
of end-organ disease related to the virus without signiﬁ cantly reduced incidence of virus 
infection.27 In 2009, a glycoprotein-B/MF59 vaccine was reported to provide 
50% protection to seronegative women of childbearing age against acquiring primary 
cytomegalovirus infection.28 We used  the same glycoprotein-B/MF59 vaccine and the 
same schedule in seronegative and seropositive transplant patients and report in this 
paper reduced viraemia and a correlate of immune control. 
Interpretation
One vaccine could be suﬃ  cient to protect both major populations at risk of 
cytomegalovirus disease, which implicates glycoprotein-B as an important component of 
any vaccine for this virus.
Articles
www.thelancet.com   Vol 377   April 9, 2011 1263
of childbearing age who are at risk from cytomegalo-
virus reinfection.
The beneﬁ cial eﬀ ects of the cytomegalovirus 
glycoprotein-B/MF59 vaccine were obtained with an 
acceptable safety proﬁ le. The only adverse event 
signiﬁ cantly increased in recipients of vaccine was pain 
at the site of injection, as was seen previously in healthy 
volunteers.20,21 We conclude therefore that vaccines 
containing cytomegalovirus glycoprotein-B should be 
assessed further in transplanted patients.
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